Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gritstone bio (GRTSQ)
OTHER OTC:GRTSQ
Holding GRTSQ?
Track your performance easily
GRTSQ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.01 - $3.17
Previous Close$0.02
Volume392.61K
Average Volume (3M)17.71M
Market Cap
$2.86M
Enterprise Value$49.68M
Total Cash (Recent Filing)$55.71M
Total Debt (Recent Filing)$102.49M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Mar 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding118,109,074
10 Day Avg. Volume74,815,685
30 Day Avg. Volume17,706,380
Standard Deviation0.52
R-Squared0.00245
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)0.16
Price to Sales (P/S)47.99
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.67
Enterprise Value/Gross Profit3.04
Enterprise Value/Ebitda-0.41
Forecast
1Y Price Target
$0.50Price Target Upside1966.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressPlans to initiate a global Phase III pivotal trial in 2025, pending FDA end of Phase II meeting and OS data availability.
Regulatory PathwayData open the door to a PFS registrational endpoint, which would speed timelines vs. OS.
Stock RatingAnalyst reiterates Market Outperform rating and risk-adjusted, DCF-derived $5 price target on Gritstone bio.
Bears Say
Clinical TrialsThe latest update included only 69 out of the 104 enrolled patients as 35 patients dropped out of the study prior to treatment, which seems disproportionately high for this patient population.
Financial PerformanceShares were trading down as much as 40% after the proposed financing announcement.
Funding And DevelopmentThe insufficient funding and lack of a clear path forward brings significant uncertainties to the development of Gritstone’s pipeline at this point.
---
Ownership Overview
9.96% Insiders
7.53% Mutual Funds
11.32% Other Institutional Investors
64.24% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GRTSQ FAQ
What was Gritstone bio’s price range in the past 12 months?
Gritstone bio lowest stock price was $0.01 and its highest was $3.17 in the past 12 months.
What is Gritstone bio’s market cap?
Currently, no data Available
When is Gritstone bio’s upcoming earnings report date?
Gritstone bio’s upcoming earnings report date is Mar 06, 2025 which is in 105 days.
How were Gritstone bio’s earnings last quarter?
Currently, no data Available
Is Gritstone bio overvalued?
According to Wall Street analysts Gritstone bio’s price is currently Undervalued.
Does Gritstone bio pay dividends?
Gritstone bio does not currently pay dividends.
What is Gritstone bio’s EPS estimate?
Gritstone bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gritstone bio have?
Gritstone bio has 118,109,080 shares outstanding.
What happened to Gritstone bio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Gritstone bio?
Among the largest hedge funds holding Gritstone bio’s share is Versant Venture Management, LLC. It holds Gritstone bio’s shares valued at 2M.
---
Gritstone bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.50 (1966.12% Upside)
$0.50 (1966.12% Upside)
Blogger Sentiment
Bullish
GRTSQ Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-98.23%
12-Months-Change
Fundamentals
Return on Equity
-201.94%
Trailing 12-Months
Asset Growth
-35.97%
Trailing 12-Months
Company Description
Gritstone bio
Gritstone Oncology, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded in August 2015 by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria and is headquartered in Emeryville, CA.
---
GRTSQ Company Deck
---
GRTSQ Earnings Call
Q1 2024
0:00 / 0:00
---
GRTSQ Stock 12 Month Forecast
Average Price Target
$0.50
▲(1966.12% Upside)
Technical Analysis
Best Analysts Covering GRTSQ
1 Year
1 Year Success Rate
5/24 ratings generated profit
1 Year Average Return
-30.50%
reiterated a buy rating 2 months ago
Copying Sean Lee CFA's trades and holding each position for 1 Year would result in 20.83% of your transactions generating a profit, with an average return of -30.50% per trade.
---